EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities

Wojciech Wiese iD, Julia Barczuk iD, Olga Racinska, Natalia Siwecka iD, Wioletta Rozpedek-Kaminska iD, Artur Slupianek, Radoslaw Sierpinski, Ireneusz Majsterek

Cancers · 05.11.2023 · 15 (21) · 5297

DOI: 10.3390/cancers15215297 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.11.2023. Verfasst von Wojciech Wiese und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, Poland, Polish National Science Centre (NCN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood malignancies remain a therapeutic challenge despite the development of numerous treatment strategies. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway plays a central role in regulating many cellular functions, including cell cycle, proliferation, quiescence, and longevity. Therefore, dysregulation of this pathway is a characteristic feature of carcinogenesis. Increased activation of PI3K/Akt/mTOR signaling enhances proliferation, growth, and resistance to chemo- and immunotherapy in cancer cells. Overactivation of the pathway has been found in various types of cancer, including acute and chronic leukemia. Inhibitors of the PI3K/Akt/mTOR pathway have been used in leukemia treatment since 2014, and some of them have improved treatment outcomes in clinical trials. Recently, new inhibitors of PI3K/Akt/mTOR signaling have been developed and tested both in preclinical and clinical models. In this review, we outline the role of the PI3K/Akt/mTOR signaling pathway in blood malignancies’ cells and gather information on the inhibitors of this pathway that might provide a novel therapeutic opportunity against leukemia.

Schlagwörter

Stichwörter der Autor:innen

Akt inhibitorsPI3K inhibitorsPI3K/Akt/mTOR pathwaydual PI3K/mTOR inhibitorsleukemiamTOR inhibitors

Autor:innen und Institutionen

  • Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.
  • Department of Pathology, Fox Chase Cancer Center, Temple University, Philadelphia, PA 19111, USA.
  • Faculty of Medicine, Cardinal Stefan Wyszyński University, 01-938 Warsaw, Poland.

ORCID-Profile: Wojciech Wiese, Julia Barczuk, Natalia Siwecka, Wioletta Rozpedek-Kaminska

Förderung

  • Medical University of Lodz, Poland
  • Polish National Science Centre (NCN)

Zitieren

APA

Wiese, W., Barczuk, J., Racinska, O., Siwecka, N., Rozpedek-Kaminska, W., Slupianek, A., Sierpinski, R., & Majsterek, I. (2023). PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers, 15(21), 5297. https://doi.org/10.3390/cancers15215297

Vancouver

Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities. Cancers. 2023;15(21):5297. doi:10.3390/cancers15215297

BibTeX
@article{Wiese2023,
  author = {Wiese, Wojciech and Barczuk, Julia and Racinska, Olga and Siwecka, Natalia and Rozpedek-Kaminska, Wioletta and Slupianek, Artur and Sierpinski, Radoslaw and Majsterek, Ireneusz},
  title = {PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {21},
  pages = {5297},
  doi = {10.3390/cancers15215297}
}
Kostenlos starten →